CN109161543B - 用于富集低频dna突变的dna探针及其应用 - Google Patents
用于富集低频dna突变的dna探针及其应用 Download PDFInfo
- Publication number
- CN109161543B CN109161543B CN201810845111.0A CN201810845111A CN109161543B CN 109161543 B CN109161543 B CN 109161543B CN 201810845111 A CN201810845111 A CN 201810845111A CN 109161543 B CN109161543 B CN 109161543B
- Authority
- CN
- China
- Prior art keywords
- dna
- mutation
- low frequency
- probe
- base peak
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000009946 DNA mutation Effects 0.000 title claims abstract description 74
- 108020003215 DNA Probes Proteins 0.000 title claims abstract description 43
- 239000003298 DNA probe Substances 0.000 title claims abstract description 43
- 230000035772 mutation Effects 0.000 claims abstract description 100
- 239000000523 sample Substances 0.000 claims abstract description 37
- 108020004414 DNA Proteins 0.000 claims abstract description 33
- 230000004048 modification Effects 0.000 claims abstract description 15
- 238000012986 modification Methods 0.000 claims abstract description 15
- 230000000295 complement effect Effects 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims description 42
- 239000011324 bead Substances 0.000 claims description 27
- 238000012163 sequencing technique Methods 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 239000002773 nucleotide Substances 0.000 claims description 20
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 238000012408 PCR amplification Methods 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 238000009396 hybridization Methods 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 6
- 108010090804 Streptavidin Proteins 0.000 claims description 5
- 238000012217 deletion Methods 0.000 claims description 5
- 230000037430 deletion Effects 0.000 claims description 5
- 238000004925 denaturation Methods 0.000 claims description 5
- 230000036425 denaturation Effects 0.000 claims description 5
- 108020004635 Complementary DNA Proteins 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 3
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 101150039808 Egfr gene Proteins 0.000 description 27
- 108700021358 erbB-1 Genes Proteins 0.000 description 27
- 210000002381 plasma Anatomy 0.000 description 27
- 238000001514 detection method Methods 0.000 description 17
- 239000000047 product Substances 0.000 description 15
- 239000006228 supernatant Substances 0.000 description 15
- 102000001301 EGF receptor Human genes 0.000 description 14
- 108060006698 EGF receptor Proteins 0.000 description 14
- 102200048928 rs121434568 Human genes 0.000 description 14
- 102200048955 rs121434569 Human genes 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 10
- 201000005249 lung adenocarcinoma Diseases 0.000 description 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 201000005202 lung cancer Diseases 0.000 description 9
- 208000020816 lung neoplasm Diseases 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 210000005259 peripheral blood Anatomy 0.000 description 9
- 239000011886 peripheral blood Substances 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000012148 binding buffer Substances 0.000 description 6
- 238000007664 blowing Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- 238000007400 DNA extraction Methods 0.000 description 3
- 108010067770 Endopeptidase K Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010064571 Gene mutation Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000036438 mutation frequency Effects 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000007480 sanger sequencing Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- 238000003260 vortexing Methods 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010071975 EGFR gene mutation Diseases 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000007847 digital PCR Methods 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 239000000439 tumor marker Substances 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102100037601 P2X purinoceptor 4 Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108010085249 Purinergic P2 Receptors Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011528 liquid biopsy Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- -1 small molecule tyrosine kinase inhibitor Chemical class 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Abstract
Description
1M NaOH | 125μL |
80mM EDTA | 100μL |
0.5g/l酚红 | 400μL |
水 | 375μL |
总体积 | 1000μL |
1M NaOH | 125μL |
80mM EDTA | 100μL |
0.5g/l酚红 | 400μL |
水 | 375μL |
总体积 | 1000μL |
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810845111.0A CN109161543B (zh) | 2018-07-27 | 2018-07-27 | 用于富集低频dna突变的dna探针及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810845111.0A CN109161543B (zh) | 2018-07-27 | 2018-07-27 | 用于富集低频dna突变的dna探针及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109161543A CN109161543A (zh) | 2019-01-08 |
CN109161543B true CN109161543B (zh) | 2021-07-23 |
Family
ID=64898521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810845111.0A Active CN109161543B (zh) | 2018-07-27 | 2018-07-27 | 用于富集低频dna突变的dna探针及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109161543B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109628560A (zh) * | 2019-01-30 | 2019-04-16 | 杭州瑞普基因科技有限公司 | 用于富集低频dna突变的dna探针及其应用 |
CN109762901B (zh) * | 2019-01-30 | 2022-11-29 | 杭州瑞普基因科技有限公司 | 用于富集低频dna突变的dna探针应用于多种突变的同时检测 |
CN110157703A (zh) * | 2019-05-21 | 2019-08-23 | 珠海圣美生物诊断技术有限公司 | 一种用于扩增变异型靶基因片段的非淬灭型寡核苷酸探针及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101608240A (zh) * | 2009-04-13 | 2009-12-23 | 厦门艾德生物医药科技有限公司 | 用于检测人类egfr基因突变的引物、探针及其使用方法 |
WO2014160797A1 (en) * | 2013-03-26 | 2014-10-02 | Genetag Technology, Inc. | Dual probe:antiprobe compositions for dna and rna detection |
CN104762408A (zh) * | 2015-04-29 | 2015-07-08 | 苏州工业园区为真生物医药科技有限公司 | 检测egfr基因突变的试剂盒及其检测方法 |
CN108048531A (zh) * | 2017-11-16 | 2018-05-18 | 苏州吉玛基因股份有限公司 | 一种高灵敏度检测稀有突变的超阻滞荧光定量pcr方法 |
-
2018
- 2018-07-27 CN CN201810845111.0A patent/CN109161543B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101608240A (zh) * | 2009-04-13 | 2009-12-23 | 厦门艾德生物医药科技有限公司 | 用于检测人类egfr基因突变的引物、探针及其使用方法 |
WO2014160797A1 (en) * | 2013-03-26 | 2014-10-02 | Genetag Technology, Inc. | Dual probe:antiprobe compositions for dna and rna detection |
CN104762408A (zh) * | 2015-04-29 | 2015-07-08 | 苏州工业园区为真生物医药科技有限公司 | 检测egfr基因突变的试剂盒及其检测方法 |
CN108048531A (zh) * | 2017-11-16 | 2018-05-18 | 苏州吉玛基因股份有限公司 | 一种高灵敏度检测稀有突变的超阻滞荧光定量pcr方法 |
Non-Patent Citations (2)
Title |
---|
R. Lin,et al..A Novel Method for Detecting Low Abundant Mutants in Three Types of Liquid Biopsies by Capturing Mutant-Alleles.《Journal of Thoracic Oncology》.2019,第14卷(第10S期), * |
Weihua Li.Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment.《Cancer Letters》.2018,第423卷(第1期), * |
Also Published As
Publication number | Publication date |
---|---|
CN109161543A (zh) | 2019-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10844436B2 (en) | Use of double-stranded DNA in exosomes: a novel biomarker in cancer detection | |
Ansari et al. | The liquid biopsy in lung cancer | |
WO2016095093A1 (zh) | 肿瘤筛查方法、目标区域变异检测方法和装置 | |
CN109161543B (zh) | 用于富集低频dna突变的dna探针及其应用 | |
CN107663533A (zh) | 一种肺癌EGFR L858R和19Del的ddPCR检测方法及应用 | |
CN110343748A (zh) | 基于高通量靶向测序分析肿瘤突变负荷的方法 | |
CN106755297A (zh) | 一组基于arms荧光定量pcr检测egfr基因t790m突变的引物组及其制备方法 | |
CN107312770A (zh) | 一种用于高通量测序检测的肿瘤brca1/2基因变异文库的构建方法及其应用 | |
CN109971832A (zh) | 一种检测基因突变的试剂盒、方法及其用途 | |
CN105063052B (zh) | 急性髓系白血病miRNA标记物 | |
CN106755551A (zh) | 一种egfr/l858r突变液体活检试剂盒及其应用 | |
CN103667267B (zh) | 用于与kras基因杂交的dna探针库及采用其富集kras基因片段的方法 | |
CN106939354B (zh) | miRNA-4530作为肺癌诊断标志物的应用 | |
CN102827935B (zh) | 定量检测FIP1L1-PDGFRA融合基因mRNA水平的试剂盒 | |
CN114350812A (zh) | 与奥西替尼耐药性相关的NSCLC-free RNA-3及其应用 | |
CN105148274B (zh) | miRNA‑885‑5p在急性髓系白血病诊治中的应用 | |
CN109762901B (zh) | 用于富集低频dna突变的dna探针应用于多种突变的同时检测 | |
CN106929599B (zh) | miRNA-6126作为肺癌诊断标志物的应用 | |
CN111808946A (zh) | 一种骨髓增生异常综合征标记物及其试剂盒 | |
CN105169393B (zh) | miRNA-548a-3p抗急性髓系白血病中的应用 | |
CN108342488A (zh) | 一种用于检测胃癌的试剂盒 | |
CN110066876A (zh) | 一种用于癌症诊断的分子标志物 | |
CN108977542A (zh) | 监控乳腺癌实时复发的寡核苷酸探针组和检测方法及应用 | |
CN110541034B (zh) | Linc01992在乳腺癌诊疗中的应用 | |
CN106967825B (zh) | miRNA-1268b作为肺癌诊断标志物的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: DNA probe for enriching low frequency DNA mutation and its application Effective date of registration: 20211206 Granted publication date: 20210723 Pledgee: Hangzhou High-tech Financing Guarantee Co.,Ltd. Pledgor: HANGZHOU REPUGENE TECHNOLOGY Co.,Ltd. Registration number: Y2021980014102 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220322 Granted publication date: 20210723 Pledgee: Hangzhou High-tech Financing Guarantee Co.,Ltd. Pledgor: HANGZHOU REPUGENE TECHNOLOGY Co.,Ltd. Registration number: Y2021980014102 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: DNA probe for enriching low frequency DNA mutation and its application Effective date of registration: 20220322 Granted publication date: 20210723 Pledgee: Shanghai Guotai Junan Securities Asset Management Co.,Ltd. Pledgor: HANGZHOU REPUGENE TECHNOLOGY Co.,Ltd. Registration number: Y2022990000158 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20221220 Granted publication date: 20210723 Pledgee: Shanghai Guotai Junan Securities Asset Management Co.,Ltd. Pledgor: HANGZHOU REPUGENE TECHNOLOGY Co.,Ltd. Registration number: Y2022990000158 |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20190108 Assignee: Hangzhou Jintou Finance Leasing Co.,Ltd. Assignor: HANGZHOU REPUGENE TECHNOLOGY Co.,Ltd. Contract record no.: X2022980028715 Denomination of invention: DNA probe for enrichment of low-frequency DNA mutation and its application Granted publication date: 20210723 License type: Exclusive License Record date: 20230112 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: DNA probe for enrichment of low-frequency DNA mutation and its application Effective date of registration: 20230115 Granted publication date: 20210723 Pledgee: Hangzhou Jintou Finance Leasing Co.,Ltd. Pledgor: HANGZHOU REPUGENE TECHNOLOGY Co.,Ltd. Registration number: Y2023980031387 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Hangzhou Jintou Finance Leasing Co.,Ltd. Assignor: HANGZHOU REPUGENE TECHNOLOGY Co.,Ltd. Contract record no.: X2022980028715 Date of cancellation: 20240327 |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20210723 Pledgee: Hangzhou Jintou Finance Leasing Co.,Ltd. Pledgor: HANGZHOU REPUGENE TECHNOLOGY Co.,Ltd. Registration number: Y2023980031387 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |